Theraclion SA (Theraclion) is a medical device company. It designs, markets, and develops high-intensity focused therapeutic ultrasound devices and equipment; and offers technical support services. The company offers echotherapy solution that combines HIFU therapy with ultrasound as a system for locating target areas for the non-invasive treatment of malignant tumors. It manufactures and markets echopulse that is used in ambulatory and non-invasive treatment of thyroid nodules and breast fibroadenoma. Theraclion’s echo pulse is used for integrated ultrasound scanners, skin contact and cooling system, scanning arms and motors, among others. It also provides EPack, which ensures cooling and coupling functions; and SONOVEIN, a robotic solution for non-invasive ecotherapy treatment of varicose veins. Theraclion is headquartered in Paris, Ile-de-France, France.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Theraclion SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Theraclion SA Company Overview
- Theraclion SA Company Snapshot
- Theraclion SA Pipeline Products and Ongoing Clinical Trials Overview
- Theraclion SA - Pipeline Analysis Overview
- Theraclion SA - Key Facts
- Theraclion SA - Major Products and Services
- Theraclion SA Pipeline Products by Development Stage
- Theraclion SA Ongoing Clinical Trials by Trial Status
- Theraclion SA Pipeline Products Overview
- EchoPulse - Breast Tumor
- EchoPulse - Breast Tumor Product Overview
- EchoPulse - Breast Tumor Clinical Trial
- Focused Ultrasound System - Prostate Tumor
- Focused Ultrasound System - Prostate Tumor Product Overview
- Focused Ultrasound System - Acute Tubular Necrosis
- Focused Ultrasound System - Acute Tubular Necrosis Product Overview
- Sonovein HD
- Sonovein HD Product Overview
- SONOVEIN System - Varicose Veins
- SONOVEIN System - Varicose Veins Product Overview
- SONOVEIN System - Varicose Veins Clinical Trial
- Theraclion SA - Key Competitors
- Theraclion SA - Key Employees
- Theraclion SA - Locations And Subsidiaries
- Head Office
- Recent Developments
- Theraclion SA, Recent Developments
- Feb 11, 2025: Theraclion Announces Treatment of First Patients With New SONOVEIN ‘SpeedPulse’ Feature Accelerating Treatment
- Feb 07, 2025: Theraclion: Publication of Adjusted Accounts for the First Half of 2024
- Jan 06, 2025: Theraclion Reviews Its 2024 Achievements
- Sep 06, 2024: Theraclion Confirms Strong Mid-Year Achievements
- Jun 24, 2024: SONOVEIN FDA Pivotal Study Treatments Completed: Theraclion Reaches Key Milestone on Schedule
- Jan 29, 2024: Theraclion Pursues Its Strategy and Announces Its 2023 Revenue
- Oct 24, 2023: Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated With SONOVEIN as Part of the FDA-approved Pivotal Study
- Apr 18, 2023: Theraclion wins FDA IDE approval for varicose veins study
- Jan 30, 2023: Theraclion announces results of first US trial
- Jan 16, 2023: Theraclion reaches major milestones in 2022, paving the way for the commercial deployment of SONOVEIN
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Theraclion SA Pipeline Products and Ongoing Clinical Trials Overview
- Theraclion SA Pipeline Products by Equipment Type
- Theraclion SA Pipeline Products by Indication
- Theraclion SA Ongoing Clinical Trials by Trial Status
- Theraclion SA, Key Facts
- Theraclion SA, Major Products and Services
- Theraclion SA Number of Pipeline Products by Development Stage
- Theraclion SA Pipeline Products Summary by Development Stage
- Theraclion SA Ongoing Clinical Trials by Trial Status
- Theraclion SA Ongoing Clinical Trials Summary
- EchoPulse - Breast Tumor - Product Status
- EchoPulse - Breast Tumor - Product Description
- EchoPulse - Breast Tumor - Focused Ultrasound with Low-dose Gemcitabine to Augment Immune Control of Early Stage Breast Cancer
- EchoPulse - Breast Tumor - Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors
- EchoPulse - Breast Tumor - Treatment of Breast Fibroadenoma Targeted Tissue with High Intensity Focused Ultrasound (HIFU)
- Focused Ultrasound System - Prostate Tumor - Product Status
- Focused Ultrasound System - Prostate Tumor - Product Description
- Focused Ultrasound System - Acute Tubular Necrosis - Product Status
- Focused Ultrasound System - Acute Tubular Necrosis - Product Description
- Sonovein HD - Product Status
- Sonovein HD - Product Description
- SONOVEIN System - Varicose Veins - Product Status
- SONOVEIN System - Varicose Veins - Product Description
- SONOVEIN System - Varicose Veins - Extracorporeal Flow Abolition in Relation With Primary Insufficiency of Great Saphenous Veins (GSV) Using High Intensity Focused Ultrasound (HIFU) Generated by Sonovein: A Multi Center Prospective Pivotal Study (VEINRESET)
- Theraclion SA, Key Employees
- Glossary
- Theraclion SA Pipeline Products by Equipment Type
- Theraclion SA Pipeline Products by Development Stage
- Theraclion SA Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- SuperSonic Imagine SA
- Alphelys Sarl
- Novacyt SA
- Adiatec, S.A.
- Mauna Kea Technologies SAS
- Carmat SAS
- Zimmer Biomet Robotics
